Globus Medical, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Keith W. Pfeil
- Full Time Employees
- 6,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2560 General Armistead Avenue Audubon PA United States of America 19403-5214
- IPO Date
- Aug 3, 2012
- CIK
- 0001237831
- Website
- globusmedical.com
- Similar Companies
- Business
- Globus Medical, Inc. is a leading musculoskeletal solutions company specializing in the design, development, manufacturing, and commercialization of a broad portfolio of products for the spine, orthopedic trauma, and neuromodulation markets. Its core product offerings include spinal implants and biologics; orthopedic trauma fixation devices such as plates, nails, and screws; joint reconstruction products including hip and knee systems; enabling technologies like surgical navigation and robotics; and high-frequency neuromodulation devices for chronic pain management. The company operates extensively across the United States and has an expanding international presence, serving hospitals, ambulatory surgery centers, and healthcare providers. Founded in 2003, Globus Medical is headquartered in Audubon, Pennsylvania. Recent major developments include the strategic acquisition of Nevro Corporation in early 2025, which significantly broadened Globus Medical's neuromodulation portfolio with advanced high-frequency spinal cord stimulation technology, positioning the company to access a $2.5 billion market opportunity. The company also continues to expand its orthopedic trauma product line with several new FDA-cleared systems in 2024 and 2025, including the TENSOR Suture Button System, ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments, and CAPTIVATE SOLA Headless Screws. Additionally, Globus Medical launched innovative anterior lumbar interbody fusion products such as the COHERE ALIF Spacer and Modulus ALIF Blades in 2025, enhancing its spine surgery portfolio. The company is undergoing integration of recent acquisitions including NuVasive to realize operational synergies while focusing on organic innovation, enhanced surgeon engagement, and scaling its hip and knee business. Globus Medical's industry segments encompass spinal surgery, orthopedic trauma, joint reconstruction, enabling surgical technologies, and neuromodulation. The company targets orthopedic surgeons, neurosurgeons, and healthcare institutions. Its growth strategy emphasizes organic product innovation combined with selective acquisitions and operational efficiency improvements under new leadership following a CEO transition in 2025. Globus Medical remains committed to advancing patient outcomes through superior engineering and a comprehensive range of musculoskeletal solutions.
Globus Medical (GMED) Upgraded to Strong Buy: Here's Why
GMED vs. ITGR: Which Stock Is the Better Value Option?
Globus Medical Q2 Earnings Call Highlights
GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution
Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript
Globus Medical Reports Second Quarter 2026 Results
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
Globus Medical, Inc. $GMED Shares Purchased by Amundi
What to Expect From These 2 MedTech Stocks This Earnings Season?
Unlocking Q2 Potential of Globus Medical (GMED): Exploring Wall Street Estimates for Key Metrics
Globus Medical, Inc. $GMED Stock Holdings Boosted by California State Teachers Retirement System
GMED's Q2 Earnings on Deck: Will Enabling Technologies Lead Results?
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
Globus Medical, Inc. $GMED Shares Bought by American Capital Management Inc.
Globus Medical, Inc. $GMED Shares Acquired by Dimensional Fund Advisors LP
Bank of New York Mellon Corp Trims Stock Position in Globus Medical, Inc. $GMED
Reasons to Retain Globus Medical Stock in Your Portfolio for Now
3 Medical Device Stocks Giving Investors a Different Healthcare Play
GMED Stock Surges 43.6% in a Year: What's Driving the Rally?